, Volume 15, Issue 9, pp 2622-2623
Date: 23 Apr 2008

Stage-Specific Guided Adjuvant Treatment for Gastric Cancer

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

To the Editor:

In the February issue of the Journal, Coburn et al.1 addressed a very critical topic: Should postoperative adjuvant treatment be tailored on the basis of pathological tumor–node–metastasis (pTNM) staging? Who are the patients most likely to benefit from adjuvant treatment: those with an early stage Ib/II or those with advanced stage III? Recently, we have also emphasized the need for pTNM staging-based selection of patients2 and there are also concerns on the use of preoperative (neoadjuvant) or perioperative chemotherapy for early-stage II gastric cancer.35

The survival benefit of adjuvant treatment has recently been well demonstrated by three pivotal randomized controlled trials (RCTs) for nonmetastatic gastric cancer.68 However, data on stage-specific efficiency of adjuvant treatment are inconsistent. The two Western trials had no the power to detect differences in tumor stage subgroup analysis.7,8 The large-scale Japanese Adjuvant Chemotherapy Trial of TS-1 for Gastr ...